Molecular Evidence of IGFBP-3 Dependent and Independent VD3 Action and Its Nonlinear Response on IGFBP-3 Induction in Prostate Cancer Cells

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2020 Aug 25

PMID 32831047

Citations 5

Authors

Ko Igarashi

Yoshihiro Yui

Kenta Watanabe

Jun Kumai

Yasuko Nishizawa

Chisato Miyaura

Masaki Inada

Satoru Sasagawa

Affiliations

Soon will be listed here.

Abstract

Background: Clinical trials have been conducted to clarify the beneficial effects of VD3 (1α,25-dihydroxy vitamin D3, also known as calcitriol) treatment in prostate cancer. However, the molecular mechanisms underlying these effects are not fully understood. Recent studies on IGFBP-3 have indicated its intracellular functions in cell growth and apoptosis. The aim of this study was to confirm the benefits of low-dose VD3 treatment and clarify the molecular mechanisms underlying these beneficial effects in prostate cancer cells.

Methods: The molecular effects of simultaneous treatment of LNCaP cells and their genetically modified cell lines with low concentration of docetaxel and VD3 were biologically and biochemically analyzed. To further determine the effects of VD3 treatment on IGFBP-3 induction system, cells were temporarily treated with VD3 in combination with a transcriptional inhibitor or protein synthesis inhibitor. Bcl-2 protein and its mRNA behavior were also observed in Igfbp-3 expression-modified LNCaP cells to determine the involvement of IGFBP-3 in the suppression of Bcl-2 by VD3 treatment.

Results: Changes in IGFBP-3 expression levels in LNCaP cells indicated that it mediated the inhibition of cell growth induced by VD3 treatment. IGFBP-3 was also found to be a mediator of the enhanced cytotoxicity of prostate cancer cells to VD3 in combination with the anti-cancer drug. We further identified the distinct property of the IGFBP-3 induction system, wherein temporal VD3 stimulation-induced prolonged IGFBP-3 expression and VD3 treatment-induced increase in IGFBP-3 expression were optimized based on the protein concentration rather than the mRNA concentration. Meanwhile, Bcl-2 expression was down-regulated by VD3 treatment in an IGFBP-3-independent manner.

Conclusion: These findings indicate the molecular mechanisms of IGFBP-3 induction stimulated by VD3 and IGFBP-3 independent Bcl-2 suppression by VD3 treatment in prostate cancer cells. The results could prompt a re-evaluation of VD3 usage in therapy for patients with prostate cancer.

Citing Articles

Improvement of histone deacetylase inhibitor efficacy by SN38 through TWIST1 suppression in synovial sarcoma.

Sasagawa S, Kumai J, Wakamatsu T, Yui Y Cancer Innov. 2024; 3(2):e113.

PMID: 38946933 PMC: 11212284. DOI: 10.1002/cai2.113.

Discordant Health Implications and Molecular Mechanisms of Vitamin D in Clinical and Preclinical Studies of Prostate Cancer: A Critical Appraisal of the Literature Data.

Fendler A, Stephan C, Ralla B, Jung K Int J Mol Sci. 2024; 25(10).

PMID: 38791324 PMC: 11120741. DOI: 10.3390/ijms25105286.

Secreted miR-210-3p, miR-183-5p and miR-96-5p reduce sensitivity to docetaxel in prostate cancer cells.

Canovai M, Evangelista M, Mercatanti A, DAurizio R, Pitto L, Marrocolo F Cell Death Discov. 2023; 9(1):445.

PMID: 38065937 PMC: 10709610. DOI: 10.1038/s41420-023-01696-4.

Expression characteristics and their functional role of IGFBP gene family in pan-cancer.

Liu Y, Shen S, Yan Z, Yan L, Ding H, Wang A BMC Cancer. 2023; 23(1):371.

PMID: 37088808 PMC: 10124011. DOI: 10.1186/s12885-023-10832-3.

IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL.

Li H, Wang D, Zhang Y, Shen D, Che Y J Oncol. 2023; 2023:1388041.

PMID: 36660244 PMC: 9845052. DOI: 10.1155/2023/1388041.

References

Budhathoki S, Hidaka A, Yamaji T, Sawada N, Tanaka-Mizuno S, Kuchiba A . Plasma 25-hydroxyvitamin D concentration and subsequent risk of total and site specific cancers in Japanese population: large case-cohort study within Japan Public Health Center-based Prospective Study cohort. BMJ. 2018; 360:k671. PMC: 5838719. DOI: 10.1136/bmj.k671. View

Rawla P . Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89. PMC: 6497009. DOI: 10.14740/wjon1191. View

Muindi J, Yu W, Ma Y, Engler K, Kong R, Trump D . CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology. 2010; 151(9):4301-12. PMC: 2940491. DOI: 10.1210/en.2009-1156. View

Goltzman D . Functions of vitamin D in bone. Histochem Cell Biol. 2018; 149(4):305-312. DOI: 10.1007/s00418-018-1648-y. View

Skowronski R, Peehl D, Feldman D . Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993; 132(5):1952-60. DOI: 10.1210/endo.132.5.7682937. View

Sharan C, Halder S, Thota C, Jaleel T, Nair S, Al-Hendy A . Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril. 2010; 95(1):247-53. PMC: 2992588. DOI: 10.1016/j.fertnstert.2010.07.1041. View

Stewart S, Dykxhoorn D, Palliser D, Mizuno H, Yu E, An D . Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 2003; 9(4):493-501. PMC: 1370415. DOI: 10.1261/rna.2192803. View

Basit S . Vitamin D in health and disease: a literature review. Br J Biomed Sci. 2014; 70(4):161-72. DOI: 10.1080/09674845.2013.11669951. View

Carlberg C, Campbell M . Vitamin D receptor signaling mechanisms: integrated actions of a well-defined transcription factor. Steroids. 2012; 78(2):127-36. PMC: 4668715. DOI: 10.1016/j.steroids.2012.10.019. View

10.

Blutt S, McDonnell T, Polek T, Weigel N . Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology. 1999; 141(1):10-7. DOI: 10.1210/endo.141.1.7289. View

11.

Lee K, Cohen P . Nuclear effects: unexpected intracellular actions of insulin-like growth factor binding protein-3. J Endocrinol. 2002; 175(1):33-40. DOI: 10.1677/joe.0.1750033. View

12.

Trump D, Aragon-Ching J . Vitamin D in prostate cancer. Asian J Androl. 2018; 20(3):244-252. PMC: 5952478. DOI: 10.4103/aja.aja_14_18. View

13.

Shimizu H, Mack T, Ross R, Henderson B . Cancer of the gastrointestinal tract among Japanese and white immigrants in Los Angeles County. J Natl Cancer Inst. 1987; 78(2):223-8. View

14.

Vuolo L, Di Somma C, Faggiano A, Colao A . Vitamin D and cancer. Front Endocrinol (Lausanne). 2012; 3:58. PMC: 3355893. DOI: 10.3389/fendo.2012.00058. View

15.

Sawada N, Inoue M, Iwasaki M, Yamaji T, Shimazu T, Sasazuki S . Plasma 25-hydroxy vitamin D and subsequent prostate cancer risk in a nested Case-Control study in Japan: The JPHC study. Eur J Clin Nutr. 2016; 71(1):132-136. DOI: 10.1038/ejcn.2016.184. View

16.

Garland C, SHEKELLE R, Barrett-Connor E, Criqui M, Rossof A, Paul O . Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet. 1985; 1(8424):307-9. DOI: 10.1016/s0140-6736(85)91082-7. View

17.

Beer T, Eilers K, Garzotto M, Egorin M, Lowe B, Henner W . Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2002; 21(1):123-8. DOI: 10.1200/jco.2003.05.117. View

18.

Peng L, J Malloy P, Wang J, Feldman D . Growth inhibitory concentrations of androgens up-regulate insulin-like growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer cells. Endocrinology. 2006; 147(10):4599-607. DOI: 10.1210/en.2006-0560. View

19.

Stewart L, Weigel N . Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate. 2005; 64(1):9-19. DOI: 10.1002/pros.20212. View

20.

Elstner E, Linker-Israeli M, Umiel T, Le J, Grillier I, Said J . Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res. 1996; 56(15):3570-6. View